Antipsychotics in patients with Alzheimer's disease - What is their clinical value?: Commentary

Nature Clinical Practice Neurology

Volumn 3, Issue 5, 2007, Pages 248-249

  Ballard, Clive ^a,c   Fossey, Jane ^b   Sharp, Samantha ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c ALZHEIMER'S SOCIETY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; MEMANTINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; BEHAVIOR DISORDER; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; RISK BENEFIT ANALYSIS; SHORT SURVEY; TREATMENT PLANNING;

EID: 34248579310     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0472     Document Type: Short Survey

References (5)

1. Ballard C and Howard R (2006) Neuroleptic drugs in dementia: Benefits and harm. Nat Rev Neurosci 7: 492-500
2. Schneider LS et al. (2005) Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 294: 1934-1943
3. Schneider LS et al. (2006) Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14: 191-210
4. McShane R et al. (2006) Memantine for dementia. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.: CD003154.pub5. DOI: 10.1002/14651858.CD003154.pub5
5. Fossey J et al. (2006) Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ 332: 756-761